Skip to main content
. 2010 Oct 12;29(1):11–16. doi: 10.1200/JCO.2010.30.0855

Fig 5.

Fig 5.

Disease-free survival (DFS) time by treatment interaction. (A) DFS before the 15-month landmark. The DFS during this initial period strongly and significantly favored the bevacizumab (Bev) arm (hazard ratio [HR], 0.61). (B) DFS subsequent to the 15-month landmark. The difference between the curves during this time was not significant (HR, 1.22). The time-by-treatment interaction using the 15-month landmark is highly significant (P < .0001).